In this three-part case study, Prof. So Yeon Jeon shares the clinical reasoning behind three treatment decisions in her anti-amyloid antibody clinic: whom to start on treatment, how to support informed consent when a family’s mind is already made up, and how to respond when ARIA appears in a patient who feels completely well.
Part 1: Deciding Whom to Treat
How eligibility, risk, and family expectations shape the decision to start treatment.
Part 2: Managing ARIA: Continue, Hold, or Stop?
Working through the decision to continue, hold, or stop treatment when ARIA occurs.
Part 3: Treating Beyond the Evidence
Weighing risks and benefits for a patient who would not have been eligible for a clinical trial.